LEM Surgical

Executive Summary

LEM Surgical AG, a Swiss medical device company founded in 2018, is pioneering the next generation of robotic surgery with its Dynamis Robotic Surgical System. Designed specifically for hard tissue procedures—such as orthopedic and neurosurgical bone and joint surgeries—Dynamis addresses the limitations of current soft-tissue robots by offering a humanoid, flexible platform optimized for precision and strength in demanding environments. The system’s unique design combines advanced robotics with intuitive control, potentially reducing operative times and improving patient outcomes in complex musculoskeletal interventions. As the global surgical robotics market expands, LEM Surgical is well-positioned to capture a significant share in the hard-tissue segment, which remains underserved by existing robotic platforms. In April 2025, LEM Surgical achieved a critical milestone with U.S. FDA clearance for the Dynamis system, validating its safety and efficacy. This regulatory approval opens the door to commercial launch in the United States, the world’s largest medical device market. The company now focuses on scaling production, building a sales and training infrastructure, and generating clinical evidence to support adoption. With a strong IP portfolio and a clear value proposition for surgeons and hospitals, LEM Surgical is on track to disrupt the orthopedic and neurosurgical robotics landscape. Near-term catalysts include initial commercial deployments, first clinical outcome publications, and potential European regulatory submissions.

Upcoming Catalysts (preview)

• Q1 2026U.S. Commercial Launch of Dynamis System80% success
• Q2 2026Publication of Initial Clinical Outcomes70% success
• Q3 2026CE Mark Submission for European Market60% success